NASDAQ:PLSE

Pulse Biosciences Competitors

$21.81
-0.21 (-0.95 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$21.19
Now: $21.81
$22.09
50-Day Range
$21.57
MA: $26.86
$35.46
52-Week Range
$6.21
Now: $21.81
$45.82
Volume60,518 shs
Average Volume147,653 shs
Market Capitalization$568.96 million
P/E RatioN/A
Dividend YieldN/A
Beta1.88

Competitors

Pulse Biosciences (NASDAQ:PLSE) Vs. INO, GNMK, SILK, ATEC, LMNX, and LUNG

Should you be buying PLSE stock or one of its competitors? Companies in the industry of "surgical & medical instruments" are considered alternatives and competitors to Pulse Biosciences, including Inovio Pharmaceuticals (INO), GenMark Diagnostics (GNMK), Silk Road Medical (SILK), Alphatec (ATEC), Luminex (LMNX), and Pulmonx (LUNG).

Pulse Biosciences (NASDAQ:PLSE) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, earnings, valuation, dividends and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Pulse Biosciences and Inovio Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pulse Biosciences00203.00
Inovio Pharmaceuticals14302.25

Pulse Biosciences currently has a consensus price target of $43.00, indicating a potential upside of 97.16%. Inovio Pharmaceuticals has a consensus price target of $17.00, indicating a potential upside of 94.95%. Given Pulse Biosciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Pulse Biosciences is more favorable than Inovio Pharmaceuticals.

Insider & Institutional Ownership

11.4% of Pulse Biosciences shares are owned by institutional investors. Comparatively, 36.0% of Inovio Pharmaceuticals shares are owned by institutional investors. 49.8% of Pulse Biosciences shares are owned by insiders. Comparatively, 4.0% of Inovio Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Pulse Biosciences and Inovio Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pulse BiosciencesN/A-156.47%-109.75%
Inovio Pharmaceuticals-8,518.10%-78.17%-40.33%

Volatility and Risk

Pulse Biosciences has a beta of 1.88, indicating that its stock price is 88% more volatile than the S&P 500. Comparatively, Inovio Pharmaceuticals has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500.

Valuation and Earnings

This table compares Pulse Biosciences and Inovio Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pulse BiosciencesN/AN/A$-46,970,000.00($2.26)-9.65
Inovio Pharmaceuticals$4.11 million441.95$-119,360,000.00($1.16)-7.52

Pulse Biosciences has higher earnings, but lower revenue than Inovio Pharmaceuticals. Pulse Biosciences is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Inovio Pharmaceuticals beats Pulse Biosciences on 7 of the 13 factors compared between the two stocks.

GenMark Diagnostics (NASDAQ:GNMK) and Pulse Biosciences (NASDAQ:PLSE) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and dividends.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for GenMark Diagnostics and Pulse Biosciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
GenMark Diagnostics05002.00
Pulse Biosciences00203.00

GenMark Diagnostics presently has a consensus target price of $22.0125, suggesting a potential downside of 8.24%. Pulse Biosciences has a consensus target price of $43.00, suggesting a potential upside of 97.16%. Given Pulse Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Pulse Biosciences is more favorable than GenMark Diagnostics.

Insider and Institutional Ownership

96.9% of GenMark Diagnostics shares are held by institutional investors. Comparatively, 11.4% of Pulse Biosciences shares are held by institutional investors. 3.3% of GenMark Diagnostics shares are held by insiders. Comparatively, 49.8% of Pulse Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares GenMark Diagnostics and Pulse Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
GenMark Diagnostics-16.95%-39.36%-13.02%
Pulse BiosciencesN/A-156.47%-109.75%

Volatility and Risk

GenMark Diagnostics has a beta of 3.02, indicating that its stock price is 202% more volatile than the S&P 500. Comparatively, Pulse Biosciences has a beta of 1.88, indicating that its stock price is 88% more volatile than the S&P 500.

Valuation & Earnings

This table compares GenMark Diagnostics and Pulse Biosciences' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GenMark Diagnostics$88.02 million19.92$-47,350,000.00($0.82)-29.26
Pulse BiosciencesN/AN/A$-46,970,000.00($2.26)-9.65

Pulse Biosciences has lower revenue, but higher earnings than GenMark Diagnostics. GenMark Diagnostics is trading at a lower price-to-earnings ratio than Pulse Biosciences, indicating that it is currently the more affordable of the two stocks.

Summary

Pulse Biosciences beats GenMark Diagnostics on 7 of the 13 factors compared between the two stocks.

Silk Road Medical (NASDAQ:SILK) and Pulse Biosciences (NASDAQ:PLSE) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and dividends.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Silk Road Medical and Pulse Biosciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Silk Road Medical02202.50
Pulse Biosciences00203.00

Silk Road Medical presently has a consensus target price of $61.75, suggesting a potential upside of 23.16%. Pulse Biosciences has a consensus target price of $43.00, suggesting a potential upside of 97.16%. Given Pulse Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Pulse Biosciences is more favorable than Silk Road Medical.

Insider and Institutional Ownership

11.4% of Pulse Biosciences shares are held by institutional investors. 7.8% of Silk Road Medical shares are held by insiders. Comparatively, 49.8% of Pulse Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Silk Road Medical and Pulse Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Silk Road Medical-53.66%-40.79%-24.56%
Pulse BiosciencesN/A-156.47%-109.75%

Volatility and Risk

Silk Road Medical has a beta of 1.41, indicating that its stock price is 41% more volatile than the S&P 500. Comparatively, Pulse Biosciences has a beta of 1.88, indicating that its stock price is 88% more volatile than the S&P 500.

Valuation & Earnings

This table compares Silk Road Medical and Pulse Biosciences' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Silk Road Medical$63.35 million27.20$-52,420,000.00($1.36)-36.87
Pulse BiosciencesN/AN/A$-46,970,000.00($2.26)-9.65

Pulse Biosciences has lower revenue, but higher earnings than Silk Road Medical. Silk Road Medical is trading at a lower price-to-earnings ratio than Pulse Biosciences, indicating that it is currently the more affordable of the two stocks.

Summary

Pulse Biosciences beats Silk Road Medical on 8 of the 12 factors compared between the two stocks.

Alphatec (NASDAQ:ATEC) and Pulse Biosciences (NASDAQ:PLSE) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and dividends.

Valuation & Earnings

This table compares Alphatec and Pulse Biosciences' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alphatec$113.43 million14.76$-57,000,000.00($1.09)-16.15
Pulse BiosciencesN/AN/A$-46,970,000.00($2.26)-9.65

Pulse Biosciences has lower revenue, but higher earnings than Alphatec. Alphatec is trading at a lower price-to-earnings ratio than Pulse Biosciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Alphatec and Pulse Biosciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Alphatec00703.00
Pulse Biosciences00203.00

Alphatec presently has a consensus target price of $15.4286, suggesting a potential downside of 12.34%. Pulse Biosciences has a consensus target price of $43.00, suggesting a potential upside of 97.16%. Given Pulse Biosciences' higher probable upside, analysts clearly believe Pulse Biosciences is more favorable than Alphatec.

Insider and Institutional Ownership

31.8% of Alphatec shares are held by institutional investors. Comparatively, 11.4% of Pulse Biosciences shares are held by institutional investors. 28.2% of Alphatec shares are held by insiders. Comparatively, 49.8% of Pulse Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Alphatec and Pulse Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Alphatec-51.95%-266.45%-40.80%
Pulse BiosciencesN/A-156.47%-109.75%

Volatility and Risk

Alphatec has a beta of 1.53, indicating that its stock price is 53% more volatile than the S&P 500. Comparatively, Pulse Biosciences has a beta of 1.88, indicating that its stock price is 88% more volatile than the S&P 500.

Summary

Pulse Biosciences beats Alphatec on 7 of the 12 factors compared between the two stocks.

Luminex (NASDAQ:LMNX) and Pulse Biosciences (NASDAQ:PLSE) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, earnings, analyst recommendations, risk and profitability.

Earnings and Valuation

This table compares Luminex and Pulse Biosciences' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Luminex$334.64 million4.66$-3,840,000.00($0.21)-156.90
Pulse BiosciencesN/AN/A$-46,970,000.00($2.26)-9.65

Luminex has higher revenue and earnings than Pulse Biosciences. Luminex is trading at a lower price-to-earnings ratio than Pulse Biosciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations for Luminex and Pulse Biosciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Luminex00103.00
Pulse Biosciences00203.00

Luminex presently has a consensus target price of $38.00, suggesting a potential upside of 15.33%. Pulse Biosciences has a consensus target price of $43.00, suggesting a potential upside of 97.16%. Given Pulse Biosciences' higher probable upside, analysts plainly believe Pulse Biosciences is more favorable than Luminex.

Insider & Institutional Ownership

88.1% of Luminex shares are held by institutional investors. Comparatively, 11.4% of Pulse Biosciences shares are held by institutional investors. 9.4% of Luminex shares are held by insiders. Comparatively, 49.8% of Pulse Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Luminex and Pulse Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Luminex4.60%3.75%2.73%
Pulse BiosciencesN/A-156.47%-109.75%

Risk & Volatility

Luminex has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500. Comparatively, Pulse Biosciences has a beta of 1.88, indicating that its share price is 88% more volatile than the S&P 500.

Summary

Luminex beats Pulse Biosciences on 8 of the 12 factors compared between the two stocks.

Pulmonx (NASDAQ:LUNG) and Pulse Biosciences (NASDAQ:PLSE) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, earnings, analyst recommendations, risk and profitability.

Earnings and Valuation

This table compares Pulmonx and Pulse Biosciences' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pulmonx$32.60 million47.60$-20,700,000.00N/AN/A
Pulse BiosciencesN/AN/A$-46,970,000.00($2.26)-9.65

Pulmonx has higher revenue and earnings than Pulse Biosciences.

Analyst Ratings

This is a summary of recent recommendations for Pulmonx and Pulse Biosciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pulmonx03502.63
Pulse Biosciences00203.00

Pulmonx presently has a consensus target price of $58.00, suggesting a potential upside of 33.39%. Pulse Biosciences has a consensus target price of $43.00, suggesting a potential upside of 97.16%. Given Pulse Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Pulse Biosciences is more favorable than Pulmonx.

Insider & Institutional Ownership

11.4% of Pulse Biosciences shares are held by institutional investors. 49.8% of Pulse Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Pulmonx and Pulse Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PulmonxN/AN/AN/A
Pulse BiosciencesN/A-156.47%-109.75%

Summary

Pulmonx beats Pulse Biosciences on 5 of the 9 factors compared between the two stocks.


Pulse Biosciences Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Inovio Pharmaceuticals logo
INO
Inovio Pharmaceuticals
1.4$8.72-0.9%$1.82 billion$4.11 million-6.41
GenMark Diagnostics logo
GNMK
GenMark Diagnostics
1.5$23.99-0.2%$1.75 billion$88.02 million-58.51
Silk Road Medical logo
SILK
Silk Road Medical
1.1$50.14-0.7%$1.72 billion$63.35 million-41.10
Alphatec logo
ATEC
Alphatec
0.8$17.60-1.3%$1.67 billion$113.43 million-16.00Analyst Report
News Coverage
Luminex logo
LMNX
Luminex
1.8$32.95-2.0%$1.56 billion$334.64 million84.49News Coverage
Gap Up
Pulmonx logo
LUNG
Pulmonx
1.4$43.48-4.7%$1.55 billion$32.60 million0.00Insider Selling
Gap Down
Cardiovascular Systems logo
CSII
Cardiovascular Systems
1.7$36.13-0.8%$1.45 billion$236.54 million-54.74
MiMedx Group logo
MDXG
MiMedx Group
1.7$12.72-5.0%$1.42 billion$299.26 million-13.53Gap Up
Atrion logo
ATRI
Atrion
1.1$644.00-0.3%$1.18 billion$155.07 million36.28
SI-BONE logo
SIBN
SI-BONE
1.2$33.76-0.5%$1.10 billion$67.30 million-21.10Insider Selling
Tactile Systems Technology logo
TCMD
Tactile Systems Technology
1.2$54.00-0.9%$1.06 billion$189.49 million-120.00News Coverage
LeMaitre Vascular logo
LMAT
LeMaitre Vascular
1.9$51.44-2.0%$1.06 billion$117.23 million55.31
Cerus logo
CERS
Cerus
1.7$6.13-1.0%$1.03 billion$74.65 million-15.72Analyst Upgrade
Analyst Revision
OrthoPediatrics logo
KIDS
OrthoPediatrics
1.5$49.55-0.0%$974.05 million$72.55 million-34.41Analyst Report
AngioDynamics logo
ANGO
AngioDynamics
1.4$23.77-1.7%$906.52 million$264.16 million-5.32
CryoLife logo
CRY
CryoLife
2.0$22.61-0.1%$884.50 million$276.22 million-59.50
Orthofix Medical logo
OFIX
Orthofix Medical
1.2$42.87-1.6%$836.48 million$459.95 million35.73
Surmodics logo
SRDX
Surmodics
1.3$57.14-0.9%$786.02 million$94.86 million714.25
OraSure Technologies logo
OSUR
OraSure Technologies
1.7$10.42-0.3%$749.68 million$154.60 million-45.30
Antares Pharma logo
ATRS
Antares Pharma
1.8$4.10-0.5%$689.46 million$123.86 million68.34Analyst Upgrade
Intersect ENT logo
XENT
Intersect ENT
1.4$20.49-1.7%$676.50 million$109.14 million-10.73News Coverage
SeaSpine logo
SPNE
SeaSpine
1.3$21.94-2.1%$612.85 million$159.08 million-13.14Analyst Report
Analyst Revision
News Coverage
Gap Down
Vapotherm logo
VAPO
Vapotherm
1.5$23.26-0.7%$600.27 million$48.10 million-11.08News Coverage
Anika Therapeutics logo
ANIK
Anika Therapeutics
1.5$39.80-1.7%$570.33 million$114.51 million-84.68News Coverage
PAVmed logo
PAVM
PAVmed
1.2$6.00-1.8%$494.77 millionN/A-7.89
Accuray logo
ARAY
Accuray
2.3$5.21-0.6%$484.00 million$382.93 million37.21
iCAD logo
ICAD
iCAD
1.5$18.55-1.0%$462.23 million$31.34 million-19.53Analyst Upgrade
ClearPoint Neuro logo
CLPT
ClearPoint Neuro
1.4$22.12-1.9%$457.29 million$11.22 million-50.27Gap Down
AVITA Medical logo
RCEL
AVITA Medical
1.4$21.07-0.2%$455.72 million$14.26 million-10.18Analyst Upgrade
Profound Medical logo
PROF
Profound Medical
1.6$20.50-3.9%$415.95 million$4.17 million-17.52News Coverage
Soliton logo
SOLY
Soliton
1.1$18.25-0.1%$386.90 millionN/A-24.33
Cytosorbents logo
CTSO
Cytosorbents
1.7$8.90-0.2%$385.05 million$24.95 million-26.97
UFP Technologies logo
UFPT
UFP Technologies
1.3$49.73-0.7%$373.97 million$198.38 million24.87
Acutus Medical logo
AFIB
Acutus Medical
1.3$13.20-0.5%$370.85 million$2.84 million0.00
Apyx Medical logo
APYX
Apyx Medical
1.0$9.50-3.7%$326.02 million$28.15 million-20.21Analyst Downgrade
Gap Up
Neuronetics logo
STIM
Neuronetics
1.5$12.79-2.5%$324.97 million$62.66 million-7.61
Utah Medical Products logo
UTMD
Utah Medical Products
0.9$87.54-1.0%$319.17 million$46.90 million27.62News Coverage
DarioHealth logo
DRIO
DarioHealth
1.1$20.62-3.9%$317.45 million$7.56 million-2.58Gap Up
IRadimed logo
IRMD
IRadimed
1.5$24.04-3.0%$295.96 million$38.52 million75.13News Coverage
Co-Diagnostics logo
CODX
Co-Diagnostics
1.6$9.10-2.2%$260.86 million$220,000.0011.23
T2 Biosystems logo
TTOO
T2 Biosystems
1.4$1.53-0.7%$227.19 million$8.34 million-2.22
Titan Medical logo
TMDI
Titan Medical
1.2$1.82-7.1%$199.34 millionN/A182.00Analyst Report
Analyst Revision
News Coverage
Gap Down
TELA Bio logo
TELA
TELA Bio
2.1$13.72-0.0%$198.12 million$15.45 million-4.71
NMRD
Nemaura Medical
0.2$6.96-3.6%$159.59 millionN/A-34.80
PolyPid logo
PYPD
PolyPid
1.4$9.33-2.0%$159.04 millionN/A0.00Gap Up
Repro Med Systems logo
KRMD
Repro Med Systems
2.0$3.44-0.6%$153.00 million$23.16 million-344.00
Apollo Endosurgery logo
APEN
Apollo Endosurgery
1.9$5.66-1.1%$147.07 million$50.71 million-4.56
Lyra Therapeutics logo
LYRA
Lyra Therapeutics
1.6$11.20-1.0%$145.02 millionN/A0.00
Avinger logo
AVGR
Avinger
1.3$1.50-0.7%$142.95 million$9.13 million-1.15News Coverage
Beyond Air logo
XAIR
Beyond Air
1.7$5.95-1.8%$121.90 million$1.39 million-3.79
This page was last updated on 4/10/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.